new semaglutide regulations fda for Novo Nordisk calls out dangers of compounded GLP-1s in new ad Semaglutide for Weight Loss in

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice

AOD-9604 vs CJC-1295/Ipamorelin The CJC-1295/Ipamorelin combination pairs a longer-acting GHRH analog (CJC-1295) with a ghrelin-mimetic secretagogue (Ipamorelin) to produce a sustained pulse of natural growth hormone release a stacking approach built entirely around amplifying the GH axis

Time will tell how well these products do in the market place, but Id be willing to bet companies like Novo Nordisk are watching closely to see whether or not they should follow suit

Patients with a BMI of 30, or a BMI of 27 with one weight-related medical condition (like high blood pressure or type 2 diabetes), are candidates for weight loss medications like GLP-1s

Severe, persistent, or focal pain is a red flag (see below)